NewslettersIntestinal Cell NewsAmMax Bio Announces First Patient Dosed in Phase IIa Study Evaluating AMB-066 in Patients with Colorectal Cancer Minimal Residual DiseaseBy Jamie Kang - January 31, 2025023AmMax Bio, Inc. announced the dosing of the first patient in its Phase IIa study evaluating AMB-066 for the treatment of patients with colorectal cancer minimal residual disease.[AmMax Bio, Inc.]Press Release